R. Brier

发表

Relationship between rat renal accumulation of gentamicin, tobramycin, and netilmicin and their nephrotoxicities

M. Brier, F. Luft, G. Aronoff, 1985, Antimicrobial Agents and Chemotherapy.

Preparation and biological evaluation of BACE1 inhibitors: Leveraging trans-cyclopropyl moieties as ligand efficient conformational constraints.

D. Timm, L. L. Winneroski, P. May, 2019, Bioorganic & medicinal chemistry.

Preparation and biological evaluation of conformationally constrained BACE1 inhibitors.

D. Timm, L. L. Winneroski, P. May, 2015, Bioorganic & medicinal chemistry.

Discovery of Cathepsin S Inhibitor LY3000328 for the Treatment of Abdominal Aortic Aneurysm.

Bruce W. Shaw, Michael A. Staszak, P. Jadhav, 2014, ACS medicinal chemistry letters.

Substituted 3-imidazo[1,2-a]pyridin-3-yl- 4-(1,2,3,4-tetrahydro-[1,4]diazepino-[6,7,1-hi]indol-7-yl)pyrrole-2,5-diones as highly selective and potent inhibitors of glycogen synthase kinase-3.

R. Campbell, P. Iversen, M. Clay, 2004, Journal of medicinal chemistry.

The development of potent and selective bisarylmaleimide GSK3 inhibitors.

R. Campbell, B. Anderson, T. Engler, 2005, Bioorganic & medicinal chemistry letters.

Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function

M. Brier, G. Aronoff, R. Sloan, 1990, Antimicrobial Agents and Chemotherapy.

Robust Pharmacodynamic Effect of LY3202626, a Central Nervous System Penetrant, Low Dose BACE1 Inhibitor, in Humans and Nonclinical Species

R. Dean, D. McKinzie, L. L. Winneroski, 2022, Journal of Alzheimer's disease reports.

The Potent BACE1 Inhibitor LY2886721 Elicits Robust Central Aβ Pharmacodynamic Responses in Mice, Dogs, and Humans

R. Dean, T. Lindstrom, D. Timm, 2015, The Journal of Neuroscience.

A CORRELATIONAL ANALYSIS OF EXPOSURE AND PHARMACODYNAMIC EFFECTS OF THE BACE1 INHIBITOR LY3202626 IN PDAPP MICE FOLLOWING ACUTE ORAL DOSING

D. McKinzie, L. L. Winneroski, P. May, 2016, Alzheimer's & Dementia.

Preclinical characterization of LY2886721: A BACE1 inhibitor in clinical development for early Alzheimer's disease

T. Lindstrom, M. Citron, P. May, 2012, Alzheimer's & Dementia.

Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor.

D. McKinzie, D. Timm, L. L. Winneroski, 2021, Journal of medicinal chemistry.